Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Jeffrey Crawford,Sudipto Mukherjee,Sepideh Shayani,Shannon Hough,David J Kuter,Sumithira Vasu,Peter Westervelt,Thomas Fynan,Adam Poust,Dwight D Kloth,Vivek Roy,Gary H Lyman,Lee S Schwartzberg,Shira Dinner,Ivana Gojo,Elizabeth A Griffiths,Mahsa Talbott,Hope S Rugo,Mary Mably,Martha Wadleigh,Douglas W Blayney,Jennifer L Burns,Ayman Saad ,Jamés O Armitage ,Pamela S Becker ,Shiven B Patel ,Raajit K Rampal ,Saroj Vadhan‐Raj ,Lia Perez ,Peter T Curtin ,Julio C Chávez ,Lenora A Pluchino

doi:10.6004/jnccn.2017.0175

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Jeffrey Crawford, Sudipto Mukherjee + Show 30 more

Open Access

https://doi.org/10.6004/jnccn.2017.0175

Copy DOI

Journal: Journal of the National Comprehensive Cancer Network	Publication Date: Dec 1, 2017
Citations: 123

Affiliation: Cancer Institute (WIA), University of Utah, City Of Hope National Medical Center, University of Michigan–Ann Arbor, Harvard University Press, The Ohio State University, Yale Cancer Center, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Mayo Clinic, University of Wisconsin–Madison, University of Tennessee Health Science Center, Johns Hopkins University, Roswell Park Cancer Institute, Vanderbilt University, University of California, San Francisco, Case Western Reserve University, Stanford University, Washington University in St. Louis, University of Alabama at Birmingham, Susan Thompson Buffett Foundation, Seattle Cancer Care Alliance, The University of Texas MD Anderson Cancer Center, University of Colorado Denver, University of Colorado Cancer Center, University of California, San Diego, Moffitt Cancer Center

#Myeloid Growth Factors #Myeloid Growth Factors Use + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of the National Comprehensive Cancer Network

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.